Filing identity and reporting period
Important identity discrepancy: The request identifies Axe Compute Inc., but the supplied filing is Skyline Medical Inc.’s Form 10-K for the fiscal year ended December 31, 2016. The summary below reflects the supplied filing, not Axe Compute Inc. This is an annual report, not a standalone fourth-quarter report.
Business context
Skyline Medical develops and sells the STREAMWAY wall-mounted system for collecting, measuring and disposing of surgical fluids directly into a facility’s sanitary sewer, plus single-use filters and cleaning solution. Its model depends on expanding system placements and recurring disposable-kit sales. The company reported approximately 100 systems sold to date and four systems sold in 2016.
Financial results and liquidity
| Metric | FY 2016 | FY 2015 |
|---|---|---|
| Revenue | $456,495 | $654,354 |
| Gross profit | $274,875 | $350,372 |
| Gross margin | 60% | 54% |
| General and administrative expense | $5,174,799 | $3,399,339 |
| Operating loss, calculated from reported operating lines | $6,526,011 | $4,399,643 |
| Net loss | $6,526,014 | $4,790,530 |
| Net cash used in operating activities | $4,381,440 | $7,487,293 |
Revenue fell about 30% year over year; management attributed the decline to a limited sales force and low brand awareness, along with time spent repositioning the installed customer base. Cost of sales also declined, and gross margin improved partly because prior-year system upgrades had raised costs. Management expected 2017 gross margin to normalize higher, but provided no quantified forecast.
At December 31, 2016, cash and cash equivalents were $1.764 million; certificates of deposit were $100,000 and marketable securities were $284,329. Current assets were $2.608 million, current liabilities $1.574 million, total liabilities $1.884 million, and stockholders’ equity $924,000. The company reported no debt at year-end. Accumulated deficit was $47.0 million.
Operating cash use averaged approximately $365,000 per month, according to management. The company raised approximately $1.740 million net in a November 2016 registered direct offering. After year-end, it raised approximately $3.509 million net in a January 2017 offering and about $350,000 net from the February over-allotment closing.
Material changes and unusual items
- G&A expense increased $1.775 million. Notable items included a former CEO separation package, increased stock-related and investor-relations expenses, and higher legal fees. The company disputed approximately $224,000 of claimed legal fees.
- Operations expense rose to $1.158 million from $847,000, including increased research and development and regulatory testing costs. R&D spending was approximately $406,000 versus $261,000.
- Interest expense declined to $3 from $391,000 in 2015; the company stated it had no debt in 2016.
- The company completed a 1-for-25 reverse stock split in October 2016. It reported 4,564,428 common shares outstanding at year-end and 6,489,428 as of March 15, 2017.
- NASDAQ extended the company’s listing-compliance deadline, then confirmed in February 2017 that the company had regained compliance with the stockholders’ equity requirement.
Outlook, risks and contingencies
Management expected continued net losses at least through the first two quarters of 2017 and said additional financing might be needed to fund operations, sales expansion, product development and international entry. The auditor reported substantial doubt about the company’s ability to continue as a going concern; the financial statements include no adjustments for the outcome of that uncertainty. The subsequent offerings improved near-term liquidity but do not eliminate the stated financing and execution risks.
- Key risks include continued cash burn, limited revenue and market acceptance, competition from larger companies, dependence on a small sales and management team, and the need to scale supply and distribution.
- International expansion depended on completing testing for the updated electrical safety standard and pursuing CE marking. The company received a Canadian medical-device establishment license in November 2016 and was negotiating distribution arrangements.
- A GLG Pharma agreement provides for up to 400,000 shares tied to development milestones, royalties on diagnostic-test sales, and exclusive distribution rights in certain European markets. The filing also identifies relationships between company directors and GLG.
- Potential contingencies include claims relating to the omission of Series C warrant shares from a later registration statement and possible claims concerning historical preemptive rights. The filing says the outcomes and potential exposure are uncertain.
- Equity financings, outstanding warrants and options, and the 2017 offering create dilution risk. The company did not expect to pay dividends in the foreseeable future.
Most important facts for investors to verify
- Confirm the issuer identity: the provided filing names Skyline Medical Inc., not Axe Compute Inc.
- Reconcile reported proceeds from the November 2016 offering: the filing gives differing gross-proceeds figures in separate passages, including approximately $1.938 million and $1.983 million; net proceeds are reported as approximately $1.740 million.
- Review the auditor’s going-concern language and assess cash runway after the 2017 offerings against the reported monthly operating cash burn.
- Verify sales traction, system placements, recurring disposable revenue, distributor agreements and the actual results of Canadian and other international expansion.
- Assess dilution from the post-year-end share issuances, outstanding warrants and options, and milestone-based GLG shares.